Get the Stockscreener App
4.31
0.46%
-0.02
Pre-market:
4.34
0.03
+0.70%
Rezolute Inc stock is traded at $4.31, with a volume of 803.72K.
It is down -0.46% in the last 24 hours and up +10.80% over the past month.
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
See More
Previous Close:
$4.33
Open:
$4.44
24h Volume:
803.72K
Relative Volume:
0.74
Market Cap:
$375.43M
Revenue:
-
Net Income/Loss:
$-69.31M
P/E Ratio:
-3.3937
EPS:
-1.27
Net Cash Flow:
$-62.80M
1W Performance:
+5.90%
1M Performance:
+10.80%
6M Performance:
-13.97%
1Y Performance:
+7.75%
1-Day Range:
$4.29
$4.44
1-Week Range:
$3.97
$4.44
52-Week Range:
$2.215
$6.1856
Rezolute Inc Stock (RZLT) Company Profile
Name
Rezolute Inc
Sector
Industry
Phone
650-206-4507
Address
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
Compare RZLT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RZLT
Rezolute Inc
|
4.31 | 375.43M | 0 | -69.31M | -62.80M | -1.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.25 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Initiated | Wedbush | Outperform |
| Aug-27-24 | Initiated | Guggenheim | Buy |
| Jul-17-24 | Initiated | BTIG Research | Buy |
| Jun-04-24 | Initiated | Craig Hallum | Buy |
| Apr-09-24 | Initiated | Maxim Group | Buy |
| Aug-02-22 | Resumed | Canaccord Genuity | Buy |
| Jun-15-22 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-08-21 | Initiated | ROTH Capital | Buy |
| May-27-21 | Initiated | Oppenheimer | Outperform |
| May-25-21 | Initiated | H.C. Wainwright | Buy |
View All
Rezolute Inc Stock (RZLT) Latest News
Rezolute, Inc. (NASDAQ:RZLT) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Rezolute’s SWOT analysis: ersodetug trials boost stock amid clinical milestones - Investing.com India
Bank of America Corp DE Has $443,000 Stock Position in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Two Sigma Investments LP Sells 12,118 Shares of Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Squarepoint Ops LLC Sells 3,980 Shares of Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Millennium Management LLC Decreases Stake in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
69,724 Shares in Rezolute, Inc. (NASDAQ:RZLT) Bought by Ameriprise Financial Inc. - Defense World
Rezolute, Inc. (NASDAQ:RZLT) is a favorite amongst institutional investors who own 77% - Yahoo Finance
BTIG maintains $15 target on Rezolute stock following trial update - Investing.com Australia
BTIG maintains $15 target on Rezolute stock following trial update By Investing.com - Investing.com India
Rezolute Announces Completion Of Enrollment In The Phase 3 Sunrize Study Of Ersodetug In Patients With Congenital Hyperinsulinism - marketscreener.com
Rezolute complete enrollment in Phase 3 sunRIZE study of ersodetug - TipRanks
Rezolute (RZLT) Completes Enrollment for Pivotal sunRIZE Study | - GuruFocus
Rezolute (RZLT) Completes Enrollment for Pivotal sunRIZE Study | RZLT Stock News - GuruFocus
Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism - The Manila Times
Man Group plc Makes New $425,000 Investment in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update - The Globe and Mail
13 Best Multibagger Stocks to Invest in Now - Insider Monkey
Rezolute, Inc. (RZLT): Analysts See 260% Upside Potential - MSN
Rezolute, Inc. (NASDAQ:RZLT) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Rezolute Inc (NASDAQ: RZLT) Is The Hottest Stock Right Now. - Stocksregister
Balyasny Asset Management L.P. Purchases New Holdings in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
HC Wainwright Analysts Lift Earnings Estimates for Rezolute - Defense World
Wedbush Forecasts Rezolute’s FY2025 Earnings (NASDAQ:RZLT) - Defense World
Rezolute (NASDAQ:RZLT) Earns Outperform Rating from Wedbush - Defense World
Rezolute (RZLT) Advances Studies on Hyperinsulinism Treatments | - GuruFocus
Rezolute (RZLT) to Release Earnings on Wednesday - Defense World
Rezolute Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Rezolute (RZLT) Advances Studies on Hyperinsulinism Treatments | RZLT Stock News - GuruFocus
Rezolute, Inc. Reports Progress on sunRIZE Enrollment and Breakthrough Therapy Designation for Ersodetug in Hypoglycemia Treatment - Nasdaq
Rezolute Secures FDA Breakthrough Status as Phase 3 Trial Nears Full Enrollment - Stock Titan
Barclays PLC Takes Position in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Hypoglycemia Market Poised for Notable Growth by 2032, Fueled - openPR.com
Rezolute Gets US FDA Breakthrough Therapy Designation for Hypoglycemia Treatment - marketscreener.com
Rezolute (RZLT) Gains FDA Breakthrough Status for Hypoglycemia T - GuruFocus
FDA grants breakthrough status to Rezolute’s hypoglycemia therapy - Investing.com
FDA grants breakthrough status to Rezolute’s hypoglycemia therapy By Investing.com - Investing.com India
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism - The Manila Times
FDA Breakthrough: New Drug Shows Promise Against Life-Threatening Tumor-Induced Hypoglycemia - Stock Titan
Renaissance Technologies LLC Reduces Stake in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Rezolute Inc (RZLT) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
Finance Watch: Biohaven Gains Up To $600m In Fresh Capital - insights.citeline.com
Rezolute to Participate in Upcoming Investor Conferences - The Manila Times
Rezolute: RZ402 Could Be A Surprise Candidate In The Making (NASDAQ:RZLT) - Seeking Alpha
Wedbush gives an Outperform recommendation for Rezolute Inc (RZLT) - knoxdaily.com
Market Recap: Rezolute Inc (RZLT)’s Positive Momentum, Closing at 3.86 - DWinneX
Rezolute’s $90 Million Common Stock Offering - Global Legal Chronicle
Rezolute (NASDAQ:RZLT) Given Buy Rating at HC Wainwright - Defense World
Geode Capital Management LLC Has $2.54 Million Stock Holdings in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Rezolute Closes $96.9 Million Underwritten Offering - TipRanks
Rezolute (RZLT) SunRIZE Trial Progresses Without Changes | RZLT Stock News - GuruFocus
Rezolute Inc Stock (RZLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rezolute Inc Stock (RZLT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kim Young-Jin | Director |
Jun 13 '25 |
Buy |
3.25 |
1,230,769 |
3,999,999 |
8,423,386 |
| KREHER NERISSA | Director |
Jun 13 '25 |
Buy |
3.25 |
3,076 |
9,997 |
37,576 |
| Hogenhuis Wladimir | Director |
Mar 31 '25 |
Buy |
2.92 |
6,758 |
19,733 |
84,025 |
| Elam Nevan C | CEO |
Mar 27 '25 |
Buy |
2.85 |
12,302 |
34,999 |
224,119 |
| Evans Daron | CFO |
Mar 26 '25 |
Buy |
2.89 |
10,000 |
28,900 |
237,900 |
| Evans Daron | CFO |
Mar 26 '25 |
Buy |
2.88 |
10,000 |
28,800 |
23,000 |
| Hogenhuis Wladimir | Director |
Feb 18 '25 |
Buy |
4.70 |
10,000 |
47,000 |
77,267 |
| Evans Daron | CFO |
Dec 18 '24 |
Buy |
4.29 |
10,000 |
42,900 |
150,900 |
| Evans Daron | CFO |
Dec 12 '24 |
Buy |
4.60 |
9,000 |
41,400 |
140,900 |
| Evans Daron | CFO |
Dec 09 '25 |
Buy |
5.04 |
10,549 |
53,167 |
131,900 |
1.02%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):